Meningitis B vaccine to be introduced in UK after U turn on its cost effectivenessBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g2327 (Published 24 March 2014) Cite this as: BMJ 2014;348:g2327
- Jacqui Wise
The meningococcal B vaccine Bexsero is to be brought into the childhood vaccination programme in the United Kingdom if it can be purchased at a low price, the Department of Health for England has said.
The decision comes after a U turn by the Joint Committee on Vaccination and Immunisation. Last July it said that the vaccine would not be cost effective in an infant vaccination programme at any price.1 However, after widespread protest, the committee carried out a consultation with stakeholders and then repeated the cost effectiveness analysis with additional information.
As a result of this new analysis the committee has now said that it would recommend Bexsero if it could be bought at a cost effective price.2 It said that cost effectiveness would be improved through the use of an abbreviated schedule at ages 2, 4, and 12 months, which would be sufficiently immunogenic.
The vaccine’s manufacturer, Novartis, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial